Dry Powder Inhaler Device Market

A dry powder inhaler (DPI) is a device that delivers medication to the lungs in the form of a dry powder. DPIs are commonly used to treat respiratory diseases such as asthma, bronchitis, emphysema and COPD although DPIs (such as inhalable insulin Afrezza) have also been used in the treatment of diabetes mellitus.
Dry Powder Inhaler Device Market contains market size and forecasts of Dry Powder Inhaler Device in global, including the following market information:

• Global Dry Powder Inhaler Device Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global Dry Powder Inhaler Device Market Sales, 2017-2022, 2023-2028, (K Units)
• Global top five Dry Powder Inhaler Device companies in 2021 (%)

The global Dry Powder Inhaler Device market was valued at 809.4 million in 2021 and is projected to reach US$ 1115.5 million by 2028, at a CAGR of 4.7% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Single Dose Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Dry Powder Inhaler Device include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, 3M, Hovione, Mannkind and Mylan, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Dry Powder Inhaler Device manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Dry Powder Inhaler Device Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Dry Powder Inhaler Device Market Segment Percentages, by Type, 2021 (%)

• Single Dose
• Multi Dose

Global Dry Powder Inhaler Device Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Dry Powder Inhaler Device Market Segment Percentages, by Application, 2021 (%)

• Asthma
• COPD
• Others

Global Dry Powder Inhaler Device Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Dry Powder Inhaler Device Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis
The report also provides analysis of leading market participants including:

• Key companies Dry Powder Inhaler Device revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Dry Powder Inhaler Device revenues share in global market, 2021 (%)
• Key companies Dry Powder Inhaler Device sales in global market, 2017-2022 (Estimated), (K Units)
• Key companies Dry Powder Inhaler Device sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• GlaxoSmithKline
• AstraZeneca
• Boehringer Ingelheim
• Chiesi
• Cipla
• 3M
• Hovione
• Mannkind
• Mylan
• Novartis
• Schering/Merck
• Teva
• Vectura

To know more about market statistics, Download a FREE Sample copy